Los Angeles Capital Management’s Kindred Biosciences, Inc. KIN Stock Holding History

Los Angeles Capital Management’s Portfolio KIN Stock Details KIN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-69,353	Closed	-$345K	–	1731
2021 Q1	$345K	Sell	69,353 -1,600	-2%	-$7.73K	﹤0.01%	1383
2020 Q4	$306K	Sell	70,953 -2,930	-4%	-$11.9K	﹤0.01%	1364
2020 Q3	$317K	Buy	73,883 +4,530	+7%	+$18.9K	﹤0.01%	1256
2020 Q2	$311K	Buy	+69,353	New	+$310K	﹤0.01%	1280

Other funds holding KIN

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Los Angeles Capital Management's KIN Position: Q2 2021 in Review

Los Angeles Capital Management sold out of Kindred Biosciences, Inc. (KIN) in Q2 2021, closing a stake of 69,353 shares — an estimated $345K sold.

Los Angeles Capital Management first reported a position in KIN in Q2 2020 and held it in 4 quarters. The position peaked at $345K in Q1 2021. 87 funds tracked by Wall St. Rank hold KIN as of Q2 2021.

Los Angeles Capital Management reported no remaining Kindred Biosciences, Inc. position as of Q2 2021 after selling out during the quarter.
Los Angeles Capital Management sold 69,353 Kindred Biosciences, Inc. shares in Q2 2021, an estimated $345K.
Los Angeles Capital Management first reported a position in Kindred Biosciences, Inc. in Q2 2020 and held it in 4 quarters.
Los Angeles Capital Management's Kindred Biosciences, Inc. position peaked at $345K in Q1 2021.
87 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q2 2021.

Based on Los Angeles Capital Management's 13F filing for Q2 2021, filed 5 Aug 2021.